Chimerism: How it Occurs and What It Means for Health

Chimerism is a condition in which two (or more) genetically distinct cell populations coexist within a single individual. Unlike mosaicism (where different cell lines arise from a single zygote due to an early mutation), in chimerism, the cell lines have different origins: they arise from the fusion of embryos, cell exchange between mother and fetus, blood transfusion, or transplantation. In practice, this can mean that the DNA of a single individual's blood, saliva, and skin are partially different. [1]

Classically, several "major" forms are distinguished: tetragametic (embryonic) chimerism, when two embryos (twins) merge into a single individual; microchimerism (the presence of a small number of "foreign" cells, usually maternal-fetal), as well as iatrogenic chimerism after blood transfusions and organ/bone marrow transplants. The degree and prevalence of chimerism vary greatly: from single cells in the blood to "bodily" distribution across many tissues. [2]

Terminologically, it's important to distinguish between "full/solid" and "micro" chimerism. In full chimerism, the proportion of "second" lineage can be high and detectable by routine tests, affecting, for example, blood type or tissue type. In microchimerism, the proportion of "foreign" cells is usually small (often <1-2%), so highly sensitive methods (qPCR, digital PCR, NGS) are used for detection. [3]

Chimerism itself is not a disease, but a biological condition with a wide variety of "consequences": from unexpected results in paternity tests and organ transplants to subtle immune effects of pregnancy and a possible link to certain autoimmune and oncological processes. Therefore, it is of interest to clinicians, geneticists, immunologists, transfusion specialists, obstetricians, and forensic experts. [4]

Main types: from embryonic to postnatal

Tetragametic (embryonic) chimerism occurs when two early twin embryos fuse to form a single individual with two cell lines. Such cases can manifest as unexpected combinations of chromosomal sex (e.g., XX and XY cells in one individual), "mismatched" genotypes of different tissues, and even false non-paternal/non-maternal results in household DNA tests. There have been real-life legal cases (such as the Lydia Fairchild case) where maternity was confirmed only after testing tissues other than blood/saliva. [5]

Twin chimerism (especially in identical/monochorionic twins, including after IVF) can occur due to vascular anastomoses between the placentas. This can cause red blood cells and even white blood cells to "exchange" between the fetuses, leading to mixed blood types and ABO "mismatches" in the laboratory. This is important to consider before blood transfusions and during typing. The rise of IVF and multiple pregnancies makes such situations more common. [6]

Microchimerism during pregnancy is a bidirectional transfer of cells between mother and fetus (fetal to mother and maternal to child). Fetal cells can persist for decades in maternal tissues (thyroid, lungs, brain, etc.), while maternal cells can persist in the child. The role of these "guests" is actively studied: they influence the development of immune tolerance, are associated with risks/protection in a number of diseases, and may participate in tissue repair. [7]

Iatrogenic chimerism occurs after transfusions and especially after allogeneic hematopoietic stem cell transplantation (HSCT), when donor cells replace the recipient's hematopoiesis (complete or mixed chimerism). Monitoring the degree of chimerism is the standard of care after HSCT (confirmation of engraftment, an early sign of leukemia relapse/rejection). Chimeric cells can also be detected after organ transplantation, which is discussed as a potential non-invasive marker of the donor-recipient immune interaction. [8]

How it is detected: methods

In clinical practice, the gold standard for blood/post-transplant chimerism remains STR typing (short polymorphic repeats) with a sensitivity of ~1-5%. For microchimerism, qPCR/digital PCR (approximately 0.1% and lower) is used, as well as NGS approaches, including the search for Y-specific sequences in the tissues of women who have given birth to sons. The choice of method depends on the task: monitoring after HSCT, forensic examination, tissue examination during pregnancy. [9]

The presence of chimerism can be confusing for diagnosticians. For example, in a recipient of HSCT, the blood DNA is actually "donor DNA," while the mucosal epithelial cells are "self-derived." In tetragametic chimerism, the saliva genotype may differ from the ovarian tissue genotype. Therefore, multiple sample types are sometimes required to accurately interpret forensic DNA, paternity tests, or clinical genetic tests. [10]

In blood groups, chimerism and mosaicism are common causes of ABO "mismatches" and atypical reactions in cross-matching. The description of "body-wide" chimerism and mosaicism as a source of ABO discordance emphasizes that laboratories should keep this possibility in mind, particularly in twins and after HSCT/transfusion. [11]

In forensic practice, microchimerism and tetragametism can lead to false "impossibility of paternity/maternity" or "mixed" DNA profiles (for example, after HSCT, when a skin swab contains cells of both genotypes). In 2023-2024, cases of pseudo-exclusion of paternity in tetragametism in the context of assisted reproductive technologies were published - another reminder of the need for a more comprehensive assessment. [12]

Pregnancy and Microchimerism: Benefits, Risks, and Mysteries

Feto-maternal microchimerism is considered a tolerance mechanism in the immune system: foreign cells teach the "self-or-foe" response and help maintain pregnancy. Modern reviews link disruptions in these processes to the risks of preeclampsia, fetal growth restriction, and adverse outcomes. Microchimerism is also considered a potential "biomarker" of pregnancy and immune memory. [13]

With regard to oncology, the data are mixed. A number of studies and meta-analyses indicate a protective effect of male fetal microchimerism against some cancers (e.g., thyroid) and possibly breast, while in other organs, opposite associations or no signal are found. The bottom line: the impact of microchimerism is context-dependent and may vary across organs and conditions. [14]

The "benefits" of fetal cells as reparative agents for maternal tissue are also being explored—there is evidence of their involvement in the remodeling of the lungs, thyroid gland, and other organs, especially after inflammation and injury. This is another possible facet of the evolutionary "cost" and "benefit" of cell exchange between generations. [15]

Maternal microchimerism can persist in children for years and is discussed in connection with autoimmune diseases (e.g., neonatal lupus, autoimmune thyroiditis), but causal relationships have not yet been proven and are actively being studied. Clinical decisions continue to be based on the overall risk profile, rather than the microchimerism itself. [16]

Transplantation and transfusion: where chimerism is a tool

After allogeneic HSCT, chimerism analysis is a routine monitoring procedure: it confirms engraftment, allows for earlier detection of hematological malignancy recurrence, and differentiates rejection from poor graft function. STR-PCR (the primary method), qPCR (more sensitive), and new NGS approaches are used; "complete," "mixed," "pre-donor," and "pre-recipient" variants are monitored. These data directly influence immunosuppressant dosages and the need for donor lymphocyte infusions. [17]

In organ transplants, the detection of donor DNA/cells ("microchimerism") is being studied as a non-invasive marker of immune interaction (including for kidney transplants). In 2023, it was shown that the level of microchimerism in some recipients correlates with graft function—a promising area, but still research-based and not a substitute for biopsy. [18]

Transfusions can cause temporary blood chimerism and affect serology. In twin infants and patients undergoing massive transfusions, this sometimes leads to "cryptic" blood types. Laboratories use expanded panels and consider the clinical context (e.g., IVF/multiple pregnancy or recent HSCT). [19]

Overall, chimerism in transplantation is not a "curiosity," but a useful monitoring tool that helps personalize therapy and promptly respond to transplant threats. Technologies continue to improve, lowering the detection threshold to fractions of a percent. [20]

Forensic Genetics and Legal Aspects: When DNA Tells Different Tales

Chimerism is one of the reasons for unexpected DNA identification results. After HSCT, the blood DNA profile matches the donor, and the epithelial profile matches the recipient; a mixture may be present on skin/surface traces. This is crucial for forensic science and the chain of custody of evidence: it is necessary to know the individual's clinical status. [21]

Embryonic chimerism can mimic the "impossibility" of paternity/maternity in standard tests. In recent years, cases have been reported where pseudo-paternity exceptions due to tetragameticism were detected in surrogacy programs and IVF. The solution is the analysis of multiple tissues (blood, saliva, cheek swab, hair, sperm/cervical epithelium) or targeted markers. [22]

Because of possible ABO discordance in chimerism, it is important to carefully interpret blood groups (and not attribute everything to a "laboratory error"): in some individuals, mosaicism/chimerism is the primary cause of "double" agglutination reactions. Clinically, this means that in-depth typing may be required before transfusion and transplantation. [23]

Ethical debates concern confidentiality (a diagnosis of chimerism may reveal pregnancy and donation history), informed consent in forensic examinations, and legal implications in paternity/maternity disputes. There are no universal rules, but the consensus is clear: if "strange" genetic results are found, chimerism should be specifically excluded. [24]

Can chimerism "hurt": the most frequently asked clinical connections

Chimerism itself is not a diagnosis and is often not felt. Potential clinical links are discussed in three areas: immunology, oncology, and tissue repair. Microchimerism may promote tolerance (e.g., to fetal/maternal antigens) and simultaneously, under certain conditions, act as a "spark" for autoimmune processes; data are conflicting and depend on the organ and context. [25]

In oncology, there are results in both directions: meta-analyses and reviews show a possible protective effect of fetal microchimerism in thyroid cancer and, probably, breast cancer; other studies show neutral or opposite signals, especially for non-core organs. The overall conclusion for 2023-2025 is that the role is ambiguous and requires stratification by tissue/fetal sex/time after birth. [26]

There is evidence that fetal cells participate in the remodeling of the lungs and other maternal organs following inflammation; mechanistically, this resembles a "mobile reserve" of stem/progenitor cells originating from the fetus. The clinical significance of these effects is still research-based, but this area is actively developing. [27]

Finally, in hematology and transfusion medicine, chimerism and mosaicism are the "usual suspects" for unexpected ABO results. These do not cause disease, but require proper transfusion tactics and precautions. [28]

Frequently asked questions

• Is it possible to “cure” chimerism?

There's usually nothing to treat here: it's a condition, not a disease. The exception is situations after HSCT/transplantation, where we manage immune therapy in response to the dynamics of chimerism (engraftment, relapse, rejection). [29]

• Will chimerism affect fertility?

In the vast majority of cases, no. With tetragametic chimerism, nuances in genetic counseling are possible; when planning IVF/donation, it is worth discussing the choice of tissue for testing with a geneticist in advance. [30]

• Why do I have "two" blood types?

This may be due to blood chimerism (such as in twins) or mosaicism. The laboratory will conduct extensive typing and make transfusion recommendations. [31]

Is it true that pregnancy "leaves the baby's cells" to the mother?

• Yes, it's called fetal microchimerism; it can persist for years and studies have shown that it has both protective and potentially pro-inflammatory effects, depending on the organ and context. [32]

When should you consider chimerism and who should you go to?

Reasons to consider include: unexplained discrepancies in DNA tests (different profiles in different tissues; "ruling out" paternity/maternity with obvious biological relationship), oddities in blood types/serology, preparation for HSCT/transplantation, as well as scientific interest in complex obstetric/immune cases. The starting point is a clinical geneticist/hematologist/transfusionist (depending on the situation). [33]

If you've had HSCT/transplantation, chimerism testing is part of your routine visits. If it's a forensic genetic issue (likely a family dispute), it's important to alert the laboratory in advance of possible chimerism and submit multiple samples. This saves time, money, and stress. [34]

During pregnancy and after childbirth, the presence of microchimerism itself does not require treatment. In cases of unusual symptoms (protracted inflammatory processes, "unclear" autoimmune manifestations), the diagnosis is not based on the chimerism itself, but on the clinical picture and current recommendations for the specific disease. [35]